Nektar Therapeutics (NKTR) stock is back in focus after peer-reviewed Phase 2b data for rezpegaldesleukin in atopic dermatitis appeared in The Lancet, highlighting statistically significant efficacy outcomes alongside a reported favorable safety profile.

Against this backdrop, Nektar Therapeutics’ recent news lands after a sharp re-rating over the year, with the share price at US$72.52 and a year to date share price return of 67.02%, alongside a very large 3 year total shareholder return of about 7x, even though the 5 year total shareholder return is still down 69.54%.

Spot emerging biotech momentum by scanning the 19 high quality undiscovered gems that, like Nektar Therapeutics after its rezpegaldesleukin data, are moving on clinical and regulatory catalysts rather than broad market swings.

After Nektar Therapeutics surged on rezpegaldesleukin headlines, the stock now trades almost 50% below the average analyst target. Does the recent move already capture the story, or does fair value sit far higher in the current range of estimates?

Most Popular Narrative: 50% Undervalued

With Nektar Therapeutics last closing at $72.52 against a narrative fair value of $144.40, the current share price sits well below that framework and puts a lot of weight on how investors view rezpegaldesleukin, future margins and long term growth.

Robust cash position after the recent equity raise extends runway into 2027, providing operational stability to advance late-stage assets and initiate Phase III trials without near-term dilution or financing risk, which supports earnings predictability and reduces financial leverage concerns.

Want to see how that cash runway bridges to the $144.40 fair value? The key assumptions mix shrinking near term revenue, higher future margins and a very punchy profit multiple.

Result: Fair Value of $144.40 (UNDERVALUED)

However, Nektar Therapeutics still faces meaningful risks, including ongoing losses, expected revenue declines, and heavy reliance on rezpegaldesleukin trial execution and regulatory outcomes.

Another View On Nektar Therapeutics Using Market Ratios

The narrative model suggests Nektar Therapeutics could have upside to $144.40, yet the current P/S of 45.4x is far above the US Pharmaceuticals industry at 5.2x, the peer average at 11.7x, and the fair ratio of 12.3x. Is the market already pricing in a lot of future success?

Next Steps

With both risks and rewards on the table for Nektar Therapeutics, now is the time to review the data yourself and act with intent. To help frame that view quickly, take a closer look at the 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond Nektar Therapeutics?

If you only focus on Nektar Therapeutics, you could miss other opportunities setting up right now, so widen your watchlist with a few targeted idea lists.

• Target potential higher upside by reviewing the 22 elite penny stocks with strong financials that combine smaller market caps with specific financial filters and growth profiles.
• Put value first and scan the 44 high quality undervalued stocks to spot stocks where quality fundamentals and current pricing appear out of sync.
• Prioritise resilience by checking the 74 resilient stocks with low risk scores that highlight companies with more robust balance sheets and lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.